At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 63 enrolled

Drug / intervention

Sunitinib +3 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00381641

NCT00381641Phase 2Completed

Compare CT.gov

Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers

National Cancer Institute (NCI)·interventional·Posted Sep 28, 2006·Updated Mar 28, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pharmacogenomic Study, and 2 other interventions for Differentiated Thyroid Gland Carcinoma and 18 related conditions. Completed, enrolled 63 participants across 17 sites.

Detailed Summary

This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Collaborators--

Timeline

Phase 2CompletedFinished

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartAug 2006

First PostedSep 2006

Primary CompletionDec 2016

Study CompletionDec 2024

TodayJul 2026

First PostedSep 28, 2006

Enrollment StartAug 29, 2006

Primary CompletionDec 31, 2016

Study CompletionDec 10, 2024

TodayJul 2, 2026

Enrollment to primary: 10.3 yearsPosted 19.8 years ago

Interventions

Laboratory Biomarker Analysisother

Optional correlative studies

Pharmacogenomic Studyother

Optional correlative studies

Sunitinibdrug

Given PO

Sunitinib Malatedrug

Given PO